Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — Sen. Bob Menendez doesn’t face reelection until 2024, but pharmaceutical executives are already flooding his campaign with cash — a sign of the central role he will play in deciding whether Democrats are able to pass substantial drug pricing reforms this year.

Since March, the New Jersey Democrat has received at least $1,000 from each of the CEOs of eight different drug companies: Pfizer, Merck, Eli Lilly, Bristol Myers Squibb, Genentech, UCB, Otsuka, and Sage Therapeutics, according to federal election disclosures. The Pfizer and Merck executives both personally gave Menendez $5,000 and $5,800, respectively. Top executives from Amgen and Lundbeck also wrote Menendez personal checks totaling $1,000 and $1,500.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.